NICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed a discount from the list price of more than £613,000 per patient.
The UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis drugs after NICE said “no” to regular NHS funding for its Epidyolex for rare forms of ch
Scotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of concerns about whether their high costs justify uncerta
